Fuller B E, Okayasu I, Simon L L, Giraldo A A, Kong Y M
Department of Immunology and Microbiology, Wayne State University School of Medicine, Detroit, Michigan 48201.
Clin Immunol Immunopathol. 1993 Oct;69(1):60-8. doi: 10.1006/clin.1993.1150.
Genetically susceptible mice develop experimental autoimmune thyroiditis (EAT) after immunization with mouse thyroglobulin (MTg). Earlier studies have shown that resistance to EAT induction can be activated by two regimens, pretreatment with deaggregated MTg (dMTg) or with thyroid-stimulating hormone (TSH). With both protocols, suppression is linked to a > or = 2-3 day increase in circulatory MTg level and is mediated by CD4+ suppressor T cells (Ts). To assess the duration of suppression, CBA (H-2k) mice were injected with dMTg or infused with TSH via an osmotic pump for 3-4 days and then challenged with MTg + adjuvant at intervals up to 73 days for dMTg-pretreated mice or up to 94 days for TSH-pretreated mice. Suppression was measurable for at least 73 days after injected dMTg. TSH-induced suppression was also long-lasting; resistance was strong 38 days after TSH infusion and was still measurable on Day 66. The Thy-1+, CD4+ Ts which transfer MTg-induced suppression were further characterized by treatment with I-J antibodies plus complement prior to transfer. This treatment abolished the transfer of suppression which acts in the afferent phase to interfere with EAT induction. The capacity of Ts to suppress the efferent phase of EAT was assessed in vitro and in vivo. Cells from dMTg-pretreated mice did not block the in vitro proliferative response of MTg-primed cells to MTg, nor did these cells, when left intact in situ, reduce the severity of disease produced by the adoptive transfer of thyroiditogenic cells. Similarly, TSH-induced suppression was ineffective in preventing adoptively transferred EAT. Since suppression, which correlates with a temporary increase of circulatory MTg, occurs only at the afferent phase of active immunization, these findings lend support to our earlier hypotheses that circulatory MTg serves a physiologic role in maintaining normal self-tolerance by sustaining low levels of Ts activation and that additional rise above baseline increases and prolongs resistance to EAT induction.
基因易感小鼠在用小鼠甲状腺球蛋白(MTg)免疫后会发生实验性自身免疫性甲状腺炎(EAT)。早期研究表明,两种方案可激活对EAT诱导的抵抗力,即用去聚合的MTg(dMTg)或促甲状腺激素(TSH)进行预处理。在这两种方案中,抑制都与循环MTg水平升高≥2 - 3天有关,并且由CD4 +抑制性T细胞(Ts)介导。为了评估抑制的持续时间,给CBA(H - 2k)小鼠注射dMTg或通过渗透泵输注TSH 3 - 4天,然后分别在长达73天(对于dMTg预处理的小鼠)或长达94天(对于TSH预处理的小鼠)的间隔时间用MTg +佐剂进行攻击。注射dMTg后,抑制作用至少可持续73天。TSH诱导的抑制作用也是持久的;TSH输注后38天抵抗力很强,在第66天仍可检测到。在转移之前,用I - J抗体加补体处理可进一步表征转移MTg诱导抑制作用的Thy - 1 +、CD4 + Ts。这种处理消除了在传入阶段起作用以干扰EAT诱导的抑制作用的转移。在体外和体内评估了Ts抑制EAT传出阶段的能力。来自dMTg预处理小鼠的细胞不会阻断MTg致敏细胞对MTg的体外增殖反应,当这些细胞原位完整保留时,也不会降低致甲状腺炎细胞过继转移所产生疾病的严重程度。同样,TSH诱导的抑制作用在预防过继转移的EAT方面无效。由于与循环MTg暂时升高相关的抑制作用仅在主动免疫的传入阶段发生,这些发现支持了我们早期的假设,即循环MTg通过维持低水平的Ts激活在维持正常自身耐受性中发挥生理作用,并且高于基线的额外升高会增加并延长对EAT诱导的抵抗力。